A Randomized, Double-Blind, Parallel-Group, 12-Week, Chronic Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 06 Aug 2018
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Pearl Therapeutics
- 17 May 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 31 May 2017 Planned End Date changed from 7 Dec 2017 to 7 Dec 2018.
- 31 May 2017 Planned primary completion date changed from 7 Dec 2017 to 7 Dec 2018.